- September 13, 2021
- Posted by: Mainframe Consulting
- Category: Business Wire
NEW YORK–(BUSINESS WIRE)–Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) on behalf of Talis stockholders. Our investigation concerns whether Talis has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On August 10, 2021, Talis reported its second quarter 2021 financial results. During the related conference call, the Company revealed that its “development timelines have been extended by delays in the launching of [Talis’] COVID-19 test and manufacturing scale.”
On this news, the Company’s stock price fell $0.58, or 6%, to close at $8.39 per share on August 11, 2021, thereby injuring investors.
Then, on August 30, 2021, after the market closed, Talis announced that its Chief Executive Officer, Brian Coe, had “stepped down.”
On this news, the Company’s stock price fell $1.00, or 11%, to close at $8.06 per share on August 31, 2021, thereby injuring investors further.
If you purchased or otherwise acquired Talis shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at firstname.lastname@example.org, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Published at Mon, 13 Sep 2021 23:00:00 +0000